Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-APEX-103: RAS(ON) inhibitors in combination with ivonescimab in solid tumors
2025-524623-50-00Phase 2Authorised
- Sponsor
- Revolution Medicines
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of ivonescimab, daraxonrasib, elironrasib and zoldonrasib in Nonhematologic neoplasms (4 arms), sponsored by Revolution Medicines. Primary endpoints: Dose-limiting toxicities and Safety and tolerability. Planned start Aug 2026; status: authorised.
02
Drugs
ivonescimabdaraxonrasibelironrasibzoldonrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-524623-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524623-50-00.